As hospitals struggle to treat the surge of pediatric respiratory syncytial virus infections with a limited repertoire of treatments, the FDA placed Pfizer’s RSV vaccine candidate on its fast-track list Dec. 7.
Read the full post on Becker's Hospital Review - Healthcare News
